Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children - Concepedia

Concepedia

Publication | Closed Access

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

142

Citations

9

References

2003

Year

Xavier Sáez‐Llorens, AVYI VIOLARI, Carl O. Deetz, Richard A. Rode, Perry Gomez, Edward Handelsman, Stephen I. Pelton, Octavio Ramilo, Pedro Cahn, Ellen G. Chadwick,

The Pediatric Infectious Disease Journal

Abstract

The liquid coformulation of lopinavir/ritonavir demonstrated durable antiviral activity and was safe and well-tolerated after 48 weeks of treatment in HIV-infected children.

References

	Year	Citations

Page 1